Association of Acute Myeloid Leukemia and Systemic Lupus Erythematosus: A Case Report
American Journal of Internal Medicine
Volume 6, Issue 1, January 2018, Pages: 25-28
Received: Mar. 2, 2018; Accepted: Mar. 14, 2018; Published: Apr. 8, 2018
Views 1847      Downloads 145
Authors
Romaric Mahutondji Massi, Department of Haematology and Paediatric Oncology, Faculty of Medecine and Pharmacy, Hassan II University, Casablanca, Morocco
Mouna Lamchahab, Department of Haematology and Paediatric Oncology, Faculty of Medecine and Pharmacy, Hassan II University, Casablanca, Morocco
Marième Camara, Departement of Hematology Laboratory, Faculty of Medecine and Pharmacy, Hassan II University, Casablanca, Morocco
Bienvenu Houssou, Department of Haematology and Paediatric Oncology, Faculty of Medecine and Pharmacy, Hassan II University, Casablanca, Morocco
Bouchra Oukkache, Departement of Hematology Laboratory, Faculty of Medecine and Pharmacy, Hassan II University, Casablanca, Morocco
Asmaa Quessar, Department of Haematology and Paediatric Oncology, Faculty of Medecine and Pharmacy, Hassan II University, Casablanca, Morocco
Article Tools
Follow on us
Abstract
Systemic lupus erythematosus is an autoimmune Inflammatory disease that can affect multiple systems and organs of the body including skin, kidneys, lungs, joints and nervous system.Some previous studies up light thatSLE was associated with increased risk of Acute leukemia (SIR = 2.3). The incidence ofthe association of AMLand SLE is not known but there are few case reports in literature. The aim of this report was to up light the difficulties wich occurred in the diagnosis and the management of acute myeloid leukemia in patient with systemic lupus erythematosus. Patient, 43 years old, diabetic treat withinsulin, wichsister is followed for Behcet's disease, was admited for AML with trisomy of chromosome 4 and 8 and thrombophlebitis of the superior sagittal sinus, Chest CT-Scan showed minimal bilateral pleural effusion. She was treated according to Morocco National protocol AML-MA-2011. CT-Scan was done atday 12 ofchemotherapy and noticedthe persistance of the minimal bilateral pleural effusion.At day 19 the patient presentedmalar rash, and right axillary adenitis. The biopsy of the adenitis show the presence of LE cells. According to internal physician recommendations we add steroids to the treatement. The cough and fever deasapear. The CT-scan for control was normal after two weeks of steroids. Patient is in complete remission after induction I. After a following-up of five months, the patient still well,but present severy infections during chemotherapy cycles and a bad tolerance for the treatement. The association SLE-AML is rare. The diagnosis of the association SLE-AML is difficult. It is management is also difficult according to commorbidity, severy infectious because of dicline of immunity, and less tolerance to AML chemotherapy.
Keywords
Acute Myeloid Leukemia, Systemic Lupus Erythematosus, Association
To cite this article
Romaric Mahutondji Massi, Mouna Lamchahab, Marième Camara, Bienvenu Houssou, Bouchra Oukkache, Asmaa Quessar, Association of Acute Myeloid Leukemia and Systemic Lupus Erythematosus: A Case Report, American Journal of Internal Medicine. Vol. 6, No. 1, 2018, pp. 25-28. doi: 10.11648/j.ajim.20180601.14
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
[2]
Emmanuel Apor,Jennifer O’Brien, Merin Stephen, Jorge J. Castillo d. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: A meta-analysis of prospective cohort studies. Leukemia Research 38 (2014) 1067–1071.
[3]
Lee SL. Clinical experience with the LE cell test. J Mount Sinai Hosp NY 1955;22:74–8.
[4]
Mary Lu, Sasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, Susan Manzi, Murray B and al. Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus. Oncology. 2013; 85(4).
[5]
Kang KY, Kim HO, Yoon HS, et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 2010;29: 381–8.
[6]
Bjorn Lofstrom, Carin Backlin, Christer Sundstrom, Eva Hellstrom-Lindberg, Anders Ekbom, Ingrid E. Lundberg. Myeloid leukaemia in systemic lupus erythematosus-a nested case–control study based on Swedish registers. Rheumatology 2009;48:1222–1226.
[7]
Juliuson G, Antunovic P, Derolf A et al. Real world data on decision to treat and outcomes from the Swedish acute Leukemia Registry. 2009 113: 4179-4187.
[8]
Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener’s Granulomatosis. Int J Cancer 2002;100:82–85.
[9]
Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004;63:1307–11.
[10]
Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013;40:666–75.
[11]
Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008;67:74–9.
[12]
Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukaemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389–98.
[13]
Ruiz-Irastorza G, Ugarte A, Egurbide MV et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007;66:815–7.
[14]
Kwong YL, Au WY, Liang RHS. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-. Cancer Genet Cytogenet 1998;103:94–7.
[15]
Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukaemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389–98.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186